Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment

被引：0
|
作者：
P. D. Miller
E. N. Schwartz
P. Chen
D. A. Misurski
J. H. Krege
机构：
[1] University of Colorado Health Sciences Center & Colorado Center for Bone Research,Department of Medicine
[2] Northern California Institute for Bone Health,Lilly Research Laboratories
[3] Eli Lilly and Company,undefined
来源：
Osteoporosis International | 2007年 / 18卷
关键词：
Adverse events; Bone mineral density; Fragility fracture; Osteoporosis; Renal impairment; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：59 / 68
页数：9
相关论文
共 50 条
  • [31] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S89 - S89
  • [32] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S59 - S60
  • [33] EFFICACY AND SAFETY OF ROMOSOZUMAB AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND MILD-TO-MODERATE CHRONIC KIDNEY DISEASE
    Miller, D.
    Adachi, J.
    Albergaria, B. -H.
    Cheung, A. M.
    Chines, A.
    Gielen, E.
    Langdahl, B.
    Miyauchi, A.
    Oates, M.
    Reid, I. R.
    Santiago, N. Ruiz
    Vanderkelen, M.
    Yang, W.
    Yu, Z.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S41 - S41
  • [34] EFFICACY AND SAFETY OF ROMOSOZUMAB AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND MILD-TO-MODERATE CHRONIC KIDNEY DISEASE
    Miller, P.
    Adachi, J.
    Albergaria, B. H.
    Cheung, A. M.
    Chines, A.
    Gielen, E.
    Langdahl, B.
    Miyauchi, A.
    Oates, M.
    Reid, I.
    Santiago, N. Ruiz
    Vanderkelen, M.
    Yang, W.
    Yu, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 185 - 185
  • [35] Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease
    Miller, Paul D.
    Adachi, Jonathan D.
    Albergaria, Ben-Hur
    Cheung, Angela M.
    Chines, Arkadi A.
    Gielen, Evelien
    Langdahl, Bente L.
    Miyauchi, Akimitsu
    Oates, Mary
    Reid, Ian R.
    Santiago, Norma Ruiz
    Vanderkelen, Mark
    Wang, Zhenxun
    Yu, Zhigang
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (08) : 1437 - 1445
  • [36] Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease
    Miller, Paul D.
    Yu, Zhigang
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 (02) : 356 - 356
  • [37] Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    R. Lindsay
    P. Miller
    G. Pohl
    E. V. Glass
    P. Chen
    J. H. Krege
    Osteoporosis International, 2009, 20 : 943 - 948
  • [38] Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis
    J. S. Hwang
    S. T. Tu
    T. S. Yang
    J. F. Chen
    C. J. Wang
    K. S. Tsai
    Osteoporosis International, 2006, 17 : 373 - 378
  • [39] Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
    Julie Satterwhite
    Michael Heathman
    Paul D. Miller
    Fernando Marín
    Emmett V. Glass
    Harald Dobnig
    Calcified Tissue International, 2010, 87 : 485 - 492
  • [40] Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis
    Kong, Meng
    Gao, Changtong
    Luan, Xiaona
    Fan, Cuiying
    Hao, Meng
    Jin, Canghai
    Zhao, Jiangning
    Li, Hongyan
    Zhao, Jindong
    Luan, Jian
    Lin, Yong
    Li, Qiang
    BMC MUSCULOSKELETAL DISORDERS, 2024, 25 (01)
12345